White males overrepresented in clinical trials for first-time cancer treatment

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Pornpak Khunatorn)
(Image: Getty/Pornpak Khunatorn)

Related tags: Clinical trial diversity, Cancer

The levels of patients enrolling for a clinical trial as a first form of treatment for cancer is 0.1%, whilst also being predominantly made up of white males with private insurance.

The researchers from Penn State Cancer institute suggested that there are two problems with this tendency: patients were not receiving treatments that were likely to increase life expectancy and also that treatments designed for the general public would not reach a diverse population.

These conclusions were drawn from data on more than 12 million patients between 2004 and 2015 in the National Cancer Database. Only 11,576 (0.1%) of these patients were enrolled in a clinical trial as a first course of therapy following cancer diagnosis.

Research by the team found that those who received the clinical trial care were more likely to live longer than patients undergoing routine treatment. When quantified, this resulted in an extended median survival of seven and a half months.

However, researchers identified two well-known issues facing clinical trial recruitment – the feeling that patients had of being ‘guinea pigs’​ and also the logistical challenge​ of finding a clinical trial center in close proximity to patients’ homes.

Diversity remains an issue

A further problem arose from this analysis – it is difficult to determine the efficacy of a treatment used in clinical trial for the general population if the treatment group is homogenous.

Researchers found that the small percentage of participants enrolling in clinical trials as a first form of therapy tended to be of a certain type: white males with private health insurance, metastatic disease, who had no other chronic medical conditions and were treated at academic medical centers.

“If clinical trials are going to be used to determine standards of care for the general population, then the study participants need to be representative of the general population — and this study shows that often this isn’t the case,”​ said Niraj Gusani, professor of surgery at the College of Medicine and senior author of the study.

The issue of increasing diversity in clinical trials is becoming a more pressing one and Outsourcing-Pharma recently held a webinar discussion​ on the topic. To this end, there have been concerted efforts​ over the years to increase the levels of women included in clinical trials.

The benefit to providing a more representational cross-section of society is not just to determine the efficacy of the drug in the general population but also that simply being part of a clinical trial improves the quality of care provided to the patient.

Nicholas Zaorsky, an assistant professor of radiation oncology at Penn State College of Medicine, who led the team of Penn State Cancer Institute researchers who analyzed the data, said: “Patients who go onto a clinical trial must be treated ​per protocol, meaning that there are many quality measures that must be met, and that there are many other health care providers looking over the patient’s care.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars